U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07615179) titled 'Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)' on May 22.
Brief Summary: The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.
Study Start Date: F...